Alaunos Therapeutics, Inc.
TCRT
$2.63
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -23.03% | 153.51% | |||
| Gross Profit | 23.67% | -153.51% | |||
| SG&A Expenses | -23.54% | -15.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.34% | 14.24% | |||
| Operating Income | 23.59% | -14.24% | |||
| Income Before Tax | 22.95% | -10.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 22.95% | -10.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 22.95% | -10.28% | |||
| EBIT | 23.59% | -14.24% | |||
| EBITDA | 23.70% | -14.25% | |||
| EPS Basic | 19.10% | 15.33% | |||
| Normalized Basic EPS | 27.67% | 15.31% | |||
| EPS Diluted | 19.10% | 15.33% | |||
| Normalized Diluted EPS | 27.67% | 15.31% | |||
| Average Basic Shares Outstanding | 6.55% | 30.23% | |||
| Average Diluted Shares Outstanding | 6.55% | 30.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||